A comprehensive view of Approved Drugs / Devices. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Novavax Inc. - Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall
Published:
April 26, 2024
by U.S. Markets (Alternative Disclosure) via PUBT
|
Pfizer gains FDA approval for its gene therapy Beqvez for hemophilia B treatment, pricing it at US$3.5M, matching the cost of the world's most expensive drug, Hemgenix; the therapy aims to provide long-term benefits and potentially reduce costs
Published:
April 26, 2024
by FiercePharma
|
Pfizer Inc Secures Patent for Modulators of Sting (Stimulator of Interferon Genes)
Published:
April 26, 2024
by Pharmaceutical Patent News
|
Pfizer gains FDA approval for BEQVEZ, a one-time dose treatment for adults with moderate to severe hemophilia B; the treatment is currently under review in Europe and was recently approved in Canada
Published:
April 26, 2024
by Pfizer Inc.
|
Merck's newly approved PAH treatment, Winrevair, forecast to reach sales of US$3.9B by 2029; the robust start to the drug's launch signals a significant boost for the company's future revenue with cancer drug Keytruda's patent expiry looming
Published:
April 25, 2024
by FiercePharma
|
Ask us about our Health Care Sector market view